Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Medicinus : Jurnal Kedokteran
Hartanto, Ericko
Unknown Affiliation
Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
The Role of Glycemic Load, Dairy, and Fatty Acids in Acne Disorders: A Systematic Review and Meta-Analysis Limanda, Claudia Felicia; Mathlubaa, Asya; Istikanto, Ferdian Harum; Sisca; Nabila, Yusra; Amalia, Shania Rizky; Putri, Syafira Ayudiah Syah; Ilmiani, Tasya Khalis; Hartanto, Ericko; Nurfadhila, Melinda
Medicinus Vol. 15 No. 1 (2025): October
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v15i1.10771

Abstract

Background: Modern dietary patterns characterized by high glycemic load, dairy consumption, and imbalanced fatty acid profiles may aggravate acne through insulin, IGF-1, and inflammatory pathways. However, findings across studies remain inconsistent. This systematic review and meta-analysis aimed to evaluate the associations between dietary glycemic load, glycemic index, dairy intake, and fatty acid composition with acne disorders. Methods: Following PRISMA 2020 guidelines, PubMed, EMBASE, and Scopus were systematically searched to September 2025. Eligible human studies assessing quantitative relationships between these dietary exposures and acne risk or severity were included. Random-effects meta-analyses were performed using the Hartung–Knapp–Sidik–Jonkman method, with effect sizes expressed as standardized mean differences (SMD) or risk ratios (RR). Result: Five studies encompassing 716 participants (426 acne, 290 controls) met the inclusion criteria. Pooled estimates indicated no significant associations for glycemic load (SMD = 0.09; 95% CI −0.30 to 0.49), glycemic index (SMD = 0.09; 95% CI −0.30 to 0.49), fatty acids/adiponectin (SMD = 0.11; 95% CI −0.74 to 0.97), or dairy consumption (RR = 1.04; 95% CI 0.25 to 4.25). Heterogeneity ranged from moderate to high (I² = 65–90%). Certainty of evidence was moderate for glycemic and dairy outcomes, and low for fatty acids. Conclusions: No significant pooled associations were observed between dietary glycemic load, dairy intake, or fatty acids and acne risk. Despite biological plausibility linking diet to acne via hormonal and inflammatory mechanisms, evidence remains inconsistent. Larger, controlled trials are warranted to define the role of nutritional interventions in acne management.
Platelet-Rich Plasma as a Novel Treatment for Hair Loss: A Systematic Review of Safety, Efficacy, and Patient Outcomes Limanda, Claudia Felicia; Hartanto, Ericko; Soewardy, Jeanny Megawati; Harahap, Alya Ihsani
Medicinus Vol. 15 No. 2 (2026): February
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v15i2.10974

Abstract

Background: Hair loss is common and clinically heterogeneous, and platelet-rich plasma (PRP) has emerged as a minimally invasive autologous therapy with potential effects on follicular cycling and the scalp microenvironment. This review evaluated PRP safety, efficacy, and patient outcomes across hair-loss conditions. Methods: PRISMA-guided systematic review and meta-analysis was conducted using PubMed, Embase, and Scopus (inception to 10 February 2026). Human clinical studies with extractable quantitative data on PRP for hair loss were included. Primary outcomes were hair density, hair thickness, hair count, and pulled hair number; safety and patient-reported outcomes were summarized. Risk of bias was assessed using ROBINS-I, and random-effects models were applied for pooling. Result: Eight studies met inclusion criteria. PRP was generally well tolerated, with mostly mild, transient procedure-related adverse events (e.g., injection-site pain, erythema/edema, pruritus, bruising) and no consistent signal of serious complications, although safety reporting was variable. Meta-analysis showed PRP increased hair density (pooled SMD = 3.39, 95% CI 2.27–4.52) and hair thickness (pooled SMD = 2.78, 95% CI 1.91–3.65) versus control, and reduced pulled hair number (pooled SMD = −3.75, 95% CI −5.59 to −1.92). Hair count was not clearly different from control (pooled SMD = −0.95, 95% CI −17.87 to 15.96). Most studies were at low-to-moderate risk of bias, with one at serious risk. Conclusions: PRP may improve hair density and thickness and reduce shedding-related measures in selected patients, but effects on hair count remain uncertain and outcomes are sensitive to protocol variability. Larger standardized randomized trials with longer follow-up are needed.
The Evolution of Biologic Therapies for Psoriasis and Atopic Dermatitis: A Systematic Review of Randomized Controlled Trial Limanda, Claudia Felicia; Hartanto, Ericko; Putri, Elisa; Primadani, Nurzanah; Hasnah, Multiyus
Medicinus Vol. 15 No. 2 (2026): February
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v15i2.10975

Abstract

ground: Psoriasis and atopic dermatitis are chronic, immune-mediated inflammatory skin diseases that cause a substantial, lifelong burden on patients globally. Over the past two decades, the therapeutic paradigm has shifted dramatically from broad immunosuppression to highly targeted biologic therapies designed to interrupt key cytokine pathways driving clinical disease activity. Methods: To comprehensively evaluate this transition, we conducted a systematic review of randomized controlled trials assessing the efficacy and safety of biologic treatments for moderate-to-severe psoriasis and atopic dermatitis. We systematically searched major electronic databases for peer-reviewed published trials, extracting data on targeted mechanisms, clinical efficacy outcomes, and safety profiles. Result: The evolution in psoriasis treatment progressed sequentially from early tumor necrosis factor inhibitors to highly specific interleukin (IL)-12/23, IL-17, and selective IL-23 blockades. These newer agents consistently demonstrate unprecedented rates of complete skin clearance and durable responses. Similarly, the atopic dermatitis landscape has been revolutionized by biologics targeting type 2 inflammation, particularly the IL-4 and IL-13 pathways. These interventions provide profound relief from intractable pruritus and persistent lesions in patients refractory to conventional therapies, while largely avoiding the off-target toxicities of older systemic agents. Conclusions: The advent and evolution of biologic therapies represent a watershed moment in dermatology. By enabling precision immunology, these targeted treatments have fundamentally transformed disease management, offering patients realistic expectations for sustained remission and significantly enhanced quality of life.
Co-Authors Amalia, Shania Rizky elisa putri Harahap, Alya Ihsani Hasnah, Multiyus Ilmiani, Tasya Khalis Istikanto, Ferdian Harum Limanda, Claudia Felicia Mathlubaa, Asya Nabila, Yusra Nurfadhila, Melinda Primadani, Nurzanah Putri, Syafira Ayudiah Syah sisca Soewardy, Jeanny Megawati